Europe is again grappling with a problem we in the US are really lucky to have avoided. European and British regulators now seem to be increasingly confident the AstraZeneca vaccine is associated with a serious but extremely rare blood-clotting side effect. Until now the UK – which has one of the world’s leading vaccination campaigns – has rejected reports of adverse side effects. But now they’re seeing them too and are recommending those under 30 get other vaccines. (There’s some indication younger people may be more susceptible to the side effect; and of course they face less threat from COVID.)
This isn’t just a major setback for Europe. It’s a major setback for the whole world. The global effort to vaccinate the populations of poorer nations (COVAX) relies heavily on the AstraZeneca vaccine because it requires less complex refrigeration and transport technology.